Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 6/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL812742 | 0.85 | CA1 (0.58) | MAPTALDH1A1AHRCA12CA1 | |
| SCHEMBL11986269 | 0.83 | CYP1A1 (0.75) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| SCHEMBL1145983 | 0.83 | CYP1A1 (0.75) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| SCHEMBL8800598 | 0.82 | CYP1A2 (0.54) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| SCHEMBL27778545 | 0.81 | CYP1A1 (0.72) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| Hydrogen Sulfide SCHEMBL17008164 | 0.81 | CYP1A1 (0.72) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| SCHEMBL21709927 | 0.81 | CYP1A1 (0.56) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| SCHEMBL21709946 | 0.81 | CYP1A1 (0.56) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| SCHEMBL4149184 | 0.81 | CYP1A1 (0.56) | CYP1A1CYP1A2CYP1B1MAPTALDH1A1 | |
| SCHEMBL21880552 | 0.79 | ESR2 (0.58) | MAPTALDH1A1AHRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182135-A1 | Amino modifiers | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090182135-A1 | Amino modifiers | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
| US-20090182135-A1 | Amino modifiers | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182135-A1 | Amino modifiers | BCAT2, AADAT, BCAT1 | CYP1A1 155/4885CYP1A2 299/4885CYP1B1 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.